DVAX - Dynavax Technologies Corp.

DVAX Stock Chart

DVAX Profile

Dynavax Technologies Corporation, headquartered in Emeryville, California, is a pioneering biopharmaceutical firm dedicated to advancing and commercializing innovative vaccines within the United States. The company's flagship product, HEPLISAV-B, is a hepatitis B vaccine approved for individuals aged 18 years and older in both the United States and Europe, designed to prevent infection from all known subtypes of the hepatitis B virus.

In addition to HEPLISAV-B, Dynavax Technologies manufactures and distributes CpG 1018, an adjuvant crucial for enhancing the immune response elicited by HEPLISAV-B. This proprietary adjuvant underscores the company's commitment to maximizing the efficacy and potency of its vaccine offerings.

Dynavax Technologies Corporation has forged strategic collaborations to bolster its vaccine development and distribution capabilities. These partnerships include agreements with Valneva Scotland Limited, Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. These collaborations facilitate the company's global reach and enable it to leverage complementary expertise in vaccine research and production.

Founded in 1996 as Double Helix Corporation and subsequently rebranded as Dynavax Technologies Corporation in September 1996, the company continues to drive innovation in vaccine development. With a strong emphasis on research and development, Dynavax Technologies aims to expand its vaccine portfolio and address critical public health needs, positioning itself at the forefront of biopharmaceutical innovation and vaccine technology.

DVAX Revenue Chart

DVAX Earnings

Analyst Ratings